

AMENDMENTS TO THE CLAIMS

Claims 1-2 (Cancelled)

Claim 3 (Currently Amended) A pharmaceutical composition which can be administered orally, consisting essentially of efletirizine as active principle, with at least one fraction which allows immediate release of the efletirizine and at least one fraction which allows prolonged release of the efletirizine, the respective amounts of active principle in the two fractions being the values included on or between the two straight lines defined by the following equations:

$$Y = -0.6786X + 56.675$$

$$Y = -0.6636X + 7.975$$

in which,

Y represents the amount of efletirizine in milligrams (mg) in the immediate-release fraction, and

X represents the amount of efletirizine in milligrams (mg) in the prolonged-release fraction, and

the total amount $X + Y$ being between 10 and 70 mg;
wherein

the two fractions are provided in the form of a two-layer tablet,
wherein

the weight ratio of the amount of active principle in the immediate-release fraction to the amount of active principle in the prolonged-release fraction is between 3 and 0.025

and wherein

~~ingestion of the pharmaceutical composition before a meal or after a meal does not significantly alter either the bioavailability or maximum plasma concentration of the active principle.~~

the composition is administered in a single daily dose, while obtaining the desired therapeutic effect.

Claim 4 (Cancelled)

Claim 5 (Cancelled)

Claim 6 (Previously Presented) The composition as claimed in claim 3, wherein the fraction which allows prolonged release of the efletirizine contains less than 5% by weight of basifying agent, weight relative to the total weight of the fraction.

Claim 7 (Cancelled)

Claim 8 (Previously Presented) The composition as claimed in claim 3, wherein the fraction which allows prolonged release of the efletirizine contains 25 mg of efletirizine and the fraction which allows immediate release of the efletirizine contains 10 mg of efletirizine.